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A B S T R A C T
Objective: To establish a new mouse model for autoimmune-type recurrent spontaneous abortion (AI-
RSA) and demonstrate the potential role of intrauterine immunization with b2GP-1-like antigen in AI-
RSA, we performed an intrauterine injection of human b2GP-1 in BALB/c mice and unrelated protein,
adjuvants, and normal saline (NS) as controls. The mean number of embryos implanted (MNEI), embryo
loss rate (ELR), mean embryo bulk (MEB), and mean placental weight (MPW) were analyzed. Compared
with the control mice, BALB/c mice injected with human b2GP-1 showed increased anti-b2GP-1 and
MPW. Moreover, BALB/c mice immunized with human b2GP-1 exhibited hypercoagulability and
vascular thrombus formation in the placenta. Electron microscopy conﬁrmed the existence of platelet
aggregation, mitochondrial swelling, and endothelial cell necrosis in the placentas of BALB/c mice
immunized with human b2GP-1. These ﬁnding indicated that intrauterine immunization with b2GP-1
successfully induced AI-RSA in mice. Increased anti-b2GP-1 antibody could independently induce
hypercoagulability, vascular endothelial injury, and vascular thrombus formation in the placenta, which
led to AI-RSA.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Anti-phospholipid antibody syndrome (APS) has been estab-
lished as one of the most frequent causes of autoimmune-type
recurrent spontaneous abortion (AI-RSA). APS is characterized by
vascular thrombosis and/or pregnancy morbidity, in association
with anti-cardiolipin antibodies (ACAs) and/or lupus anti-coagu-
lant (LA) and/or anti-b2GP-1 antibodies [1].
Anti-b2GP-1 antibody is a biomarker for the diagnosis of APS.
More than 10 studies have conﬁrmed that an increased IgG anti-
b2GP-1 antibody level is an independent risk factor for venous
thrombosis and fetal loss [2–4]. ‘‘Intra-placental thrombosis’’ has
traditionally been presumed to play a role in the fetal loss in APS
patients [5], but no direct evidence has been reported. To clarify
the pathogenic role of anti-b2GP-1 antibodies in both thrombosis* Corresponding author. Tel.: +86 21 68383071; fax: +86 21 68383073.
E-mail address: zamzkh0526@126.com (A. Zhao).
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0301-2115/ 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access
nd/3.0/).and fetal loss, several animal models have been established for the
study of APS since the 1990s [1]. In a previous study, mouse
footpad immunization with human b2GP-1 resulted in elevated
antibodies against negatively charged phospholipids, fetal loss,
prolonged activated partial thromboplastin time (APTT), and
thrombocytopenia, without evidence for thrombus formation
[2]. Recently, Arad et al. found that anti-b2GP-1 antibodies from
patients with APS induced arterial thrombus formation in a mouse
model [3]. However, no available animal model reproduces the full
range of clinical manifestations observed in the human syndrome.
Most studies have shown either fetal loss or thrombosis, not both.
Herein, we immunized BALB/c mice by intrauterine injection
with human b2GP-1 and included unrelated protein, adjuvants,
and normal saline (NS) as controls. BALB/c mice injected with
b2GP-1 developed high concentrations of anti-b2GP-1 antibodies.
Moreover, they also showed both fetal loss and thrombus
formation in the placenta. This study demonstrates that anti-
b2GP-1 antibodies independently induce fetal resorption and
thrombus formation in the placenta, which may be the primary
mechanism of recurrent abortion.article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
S. Xiao et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 178 (2014) 84–88 85Mice
Six- to 8-week-old female BALB/c mice were purchased from
the Laboratory Animal Center of Shanghai, The Chinese Academy of
Science. Genetic monitoring conﬁrmed that the mice were up to
the international standard of quality. The study was approved by
the Institutional Review Board of Ren Ji Hospital, School of
Medicine, Shanghai Jiao Tong University.
Intrauterine injection method
A self-designed injection syringe was used for intra-uterine
injection. The TIP (Axygen, USA) was heated for 3–5 s using a Spirit
Lamp, and the melted tips were then elongated to 3 cm and a
diameter of 1 mm (Fig. 1A). We termed it an intrauterine injection
syringe when it was attached to a 1 ml injection syringe. Using this
intrauterine injection syringe, the antigen and the control formula-
tions were injected into the uterine cavity through the vagina and
cervix (Fig. 1B). Dye injection was ﬁrst used to test this injection
method. We observed that the uterus and not the peritoneal tissue
ﬁlled with dye when the needle was manipulated gently (Fig. 1C).
Immunization
Fifteen BALB/c female mice were immunized in the uterine
cavity with 10mg of human b2GP-1 (Cell Sciences, USA) mixed
with CFA (Sigma, USA). One week later, the mice were immunized
again with 10 mg of human b2GP-1 in IFA (Sigma, USA). The
unrelated protein and adjuvants were injected into the uterine
cavity as controls (6–15mice/group).Mice immunizedwithb2GP-
1 were observed in four replicate groups. Ten days after active
immunization, BALB/c female mice were paired overnight with
males. Mating was evidenced by the appearance of a vaginal plug
the following morning.
Evaluation of pregnancy outcome
All plugged females were sacriﬁced by cervical dislocation on
days 12–14, the uteri were removed, and the total number of
implantations and resorption sites were recorded, as described by
Bertoja et al. [4]. The MNEI was calculated as the number of total
fetuses divided by the total number of mice. The ELR was
calculated as the number of resorbed fetuses divided by the
number of resorbed and full-term fetuses. The MPW (g) was
calculated as the total placenta weight divided by the number of
full-term fetuses. The MEB was calculated using the following
formula: MEB (mm3) = 0.5  length-diameter  short diameter2.
ELISA
Blood sampleswere collected on day 14, and the serum levels of
ACA and anti-b2GP-1 antibodiesweremeasured by ELISA. The ACA
ELISA (EUROIMMUN, Germany) was performed according to the
manufacturer’s protocol, The intra- and inter-assay coefﬁcients of
variation are respectively 7.5% and 10.5%. Theminimumdetectable
amount of the assayed substance is 2 U/ml. Anti-b2GP-1 activity
was detected by a solid-phase ELISA similar to a previous report
[4]. Plates were coated with puriﬁed b2GP-1 (5mg/ml) in PBS
overnight. The coated plates were then blocked with 2% BSA and
incubated with serial dilutions of test serum. After washing, the
plates were incubated with a diluted goat anti-mouse IgG HRP
conjugate (1/5000) and developed with 1 mg/ml p-nitrophenyl-
phosphate in diethanolamine buffer for 15–20 min. The intra- and
inter-assay coefﬁcients of variation are respectively 8.0% and
11.3%, theminimumdetectable amount of the assayed substance is
2 U/ml.Blood cell counts and coagulation studies
Platelets from mouse blood samples were counted using the
Sysmex XT-1800i Automated Hematology Analyzer. Anticoagulant
activity was evaluated by the APTT, prothrombin time (PT), and
ﬁbrinogen (FIB) level obtained using the Sysmex CA-7000
Automated Blood Coagulation Analyzer.
Placental pathology
Pathological changes in the placenta were observed by H&E
staining and electronmicroscopy (PHILIP CM-120). The presence of
thrombus was evaluated independently by two pathologists (Dr.
Yao and Dr. Yan).
Statistical analysis
Data are expressed as the mean  SD. ANOVA followed by post
hoc testwas carried out for the statistical analysis. The p values < 0.05
were considered statistically signiﬁcant.
Characterization of serological features of BALB/c mice following
intrauterine injection
Six- to eight-week-old female BALB/c mice were immunized
with b2GP-1 via intrauterine injection. Fourteen days after the
injection, we examined the concentrations of anti-b2GP-1
antibody and ACAs in the serum from mice in the CFA/b2GP-1
group and the control group. The concentration of anti-b2GP-1
antibodies in the CFA/b2GP-1 group was signiﬁcantly higher
compared to the control group (p < 0.05), whereas there were no
signiﬁcant differences in the ACA concentrations among all groups
(p > 0.05) (Fig. 1D). These results indicated that intrauterine
injection successfully induced a high anti-b2GP-1 antibody
concentration in BALB/c mice.
Intrauterine injection with human b2GP-1 leads to a high rate of
abortion
To identify the effect of increased anti-b2GP-1 antibody on
embryo resorption, all pregnant mice were sacriﬁced 12–14 days
after plug formation, and the embryos and the placenta were
further analyzed. We found that the rate of resorption (23.36%) in
the CFA/b2GP-1 group was signiﬁcantly higher compared to the
control groups (4.23–10.19%). Moreover, BALB/c mice immunized
with 10mg ofb2GP-1 developed a signiﬁcantly lighter and smaller
placenta and embryos compared to the CFA/BSA, CFA, and NS
groups (p < 0.05) (Fig. 1E). Representative resorbed fetuses are
shown in Fig. 1E. No signiﬁcant difference in the MNEI was
observed among all groups (Table 1). These results suggested that
the intrauterine injection of b2GP-1 induced fetal resorption and
had no obvious effect on fertility or embryo implantation.
Interestingly, a Pearson correlation analysis demonstrated no
signiﬁcant correlation between the anti-b2GP-1 antibody concen-
tration and the rate of embryo loss in the CFA/b2GP-1 group
(r = 0.369, p = 0.176).
Coagulation state
Previous reports on the effect of anti-b2GP-1 antibodies on
PT, FIB, and platelet count were controversial [2,3]. In our
intrauterine injection mouse model, we found that pregnant
mice injected with b2GP-1 had a higher level of FIB (p < 0.05)
(Table 2). However, the PT, APTT and platelet count did not
signiﬁcantly differ between b2GP-1-immunized mice and the
other groups (Table 2).
[(Fig._1)TD$FIG]
Fig. 1. Establishment of the recurrent abortion model. (A) Self-designed plastic injector; (B) intrauterine injection of a pregnant mouse; (C) dye staining of uterus following
dye injection. The uteruswas full of dye, but the peritoneal tissuewas not stained; (D) concentration of anti-b2GP-1 antibodies and ACAs in sera obtained from BALB/c female
mice. Comparedwith the control groups, the concentration of anti-b2GP-1 antibodies in the CFA/b2GP-1 groupwas signiﬁcantly higher; and (E) typical uterus from amouse
immunizedwithb2GP-1(right). The arrow indicates resorption. The bar shows the percentage of fetal loss in the different groups (left). The p valuewas obtained fromANOVA
followed by post hoc test. *p < 0.05.
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intrauterine injection of b2GP-1
Previous studies have shown that anti-b2GP-1 antibody can
induce thrombus formation. To determine whether immunizationwith b2GP-1 can induce thrombus formation in the placenta and
disrupt the blood supply to the fetus, we analyzed the histological
characteristics of placentas from BALB/c mice following the
intrauterine injection of b2GP-1 or control preparations. H&E
staining showed vascular thrombosis in the placentas of almost all
Table 1
Effects of active immunization in the uterine cavity on the outcome of pregnancy.
N MNEI MPW (g) MEB (mm3)
Normal 15 9.51.4 0.0960.005 0.174 0.026
CFA/b2GP-1 15 9.52.8 0.0890.008* 0.160 0.039*
CFA/BSA 6 9.01.4 0.0990.007 0.173 0.029
CFA 13 8.31.4 0.0950.004 0.175 0.047
NS 10 9.61.6 0.0970.005 0.171 0.041
* p<0.05 compared with other groups. The p-values were obtained by ANOVA
and SNK-q test.
Table 2
Platelet count, PT, and FIB in all groups.
Platelet count.
no. (ml)
PT (s) APTT (s) FIB (g/l)
Normal 392.1328.28 18.094.83 52.5116.16 1.20 0.16
CFA/b2GP-1 382.7316.82 14.792.58 49.9516.14 1.45 0.16*
CFA/BSA 397.4022.07 17.833.86 56.5614.64 1.23 0.19
CFA 392.6726.72 17.883.23 53.507.12 1.28 0.21
NS 398.1032.15 17.793.54 56.159.91 1.23 0.15
*p<0.05 compared with the other groups. The p-values were obtained by ANOVA
and SNK-q test.
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observed in the placentas of mice injected with unrelated protein,
adjuvants and NS (Fig. 2B). Fisher’s exact test demonstrated a
signiﬁcant difference in thrombus formation among b2GP-1-
immunized mice and the control groups (p < 0.05, Fig. 2C). A
previous study showed that anti-lipid antibody could disrupt the
trophoblast and induce thrombosis in the placenta.[(Fig._2)TD$FIG]
Fig. 2. Pathological analysis of placental tissue (H&E). (A) H&E staining of placental tissue
with RBCs are indicated with arrows. No inﬂammatory cell invasion was observed. (A) R
H&E staining of placental tissue from control groups, lightmicroscopy (200). Normal blo
was observed; (C) the percentage of placentas with thrombus formation. The percentage
(n = 15), and the percentages of mice with a placental vascular thrombus in the normal, C
(n = 10), respectively. The p value was obtained from ANOVA followed by an appropriate
AI-RSAmodel was analyzed by electron microscopy. Right: platelet aggregation is indicat
(17,500). Left: endothelial cell necrosis is indicated with an arrow (4200).We used electron microscopy to explore the detailed patholog-
ical changes in the placenta induced by increased anti-b2GP-1
antibodies. Electron microscopy conﬁrmed the existence of
platelet aggregation, mitochondrial swelling, and endothelial cell
necrosis in the placentas of mice injected with b2GP-1 (Fig. 2D).
APS is an autoimmune disorder caused by antiphospholipid
antibodies, and 15% of APS patients exhibit RSA [6]. Thefrom the AI-RSAmousemodel, light microscopy (200). Normal blood vessels ﬁlled
ed thrombus is indicated by the arrowhead, with inﬂammatory cell inﬁltration; (B)
od vessels ﬁlledwith RBCs are indicatedwith arrows. No inﬂammatory cell invasion
of mice with a placental vascular thrombus in the AI-RSA mouse model was 93.3%
FA/BSA, CFA, and NS groups were 6.7% (n = 15), 16.7% (n = 6), 7.7% (n = 13) and 10.0%
d post hoc test. *p < 0.05; (D) the ultrastructure of placental tissue from the murine
ed with arrows (13,500). Middle: mitochondrial swelling is indicated with arrows
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although it is hypothesized that placental thrombosis causes
infarction and eventual fetal death. However, these proposed roles
in APS are only based on observations of extensive placental
infarction and thrombosis in failed pregnancies in women with
APS [7–9]. Further investigations are needed to better understand
the mechanisms leading the production of these antibodies and
how antiphospholipid antibodies induce RSA.
Reproductive tract infection is a major cause for the risk of
abortion [10–13]. Intrauterine infection provides the chance that
the immune system contacts with the mimicry antigen. It is
supposed reproductive tract infection with some bacteria or
viruses with b2GP-1 mimicry molecules might induce APS
[14,15]. In this study, we established an intrauterine injection
method to induce high anti-b2GP-1 antibody levels in mice to
explore the role of anti-b2GP-1 antibodies in RSA. Our ELISA
results showed that anti-b2GP-1 antibody was highly induced
in mice following the intrauterine injection of b2GP-1. However,
no signiﬁcant difference was found in the anti-ACA antibody
concentration between mice that received an intrauterine
injection of b2GP-1 and the control groups. These results
indicated that the intrauterine injection of b2GP-1 could
successfully and speciﬁcally induce a high anti-b2GP-1 antibody
level in mice.
Interestingly, signiﬁcantly higher ELR and lower MEB andMPW
were found in mice injected with b2GP-1. Because anti-ACA
antibody was not increased in this mouse model, these results also
strongly indicate that anti-b2GP-1 antibody is an independent risk
factor for RSA [16]. No signiﬁcant difference in the MNEI was
observed among the groups in our study, suggesting that the
administration of human b2GP-1 to the mouse uterus does not
affect fertility or embryo implantation in mice.
Autoantibodies are thought to affect coagulation, resulting in
decidua vascular lesions, placental thrombosis, and infarction,
which are harmful to placental function and cause embryo
necrosis. As a result, they may be the primary pathophysiological
mechanism behind AI-RSA [17,18]. Blood hypercoagulabity is
commonly observed in patients with APS and manifests as plasma
viscosity, blood viscosity, platelet aggregation, and increased
platelet granule protein expression. The administration of aspirin
and heparin as an anticoagulant therapy is often efﬁcacious in APS
patients [19,20]. Consistent with these characteristics of APS in
humans, we found that the FIB level was signiﬁcantly increased in
mice immunized with b2GP-1 compared to the control groups.
Moreover, vascular thrombosis was found by H&E staining in the
placentas of mice immunized with b2GP-1. Electron microscopy
conﬁrmed the existence of platelet aggregation, mitochondrial
swelling, and endothelial cell necrosis. It should be noticed that
inﬂammation and complement activationmight also have a crucial
role based on in vivo studies using different mouse models of
APS [21–24]. Further studied on this mouse model should be
performed in the future.
In summary, our mouse model of the intrauterine injection of
b2GP-1 induced anti-b2GP-1 antibody production and RSA. This
induction demonstrated the pathogenic potential of anti-b2GP-1
antibodies and provided direct evidence that anti-b2GP-1
antibodies were able to induce blood hypercoagulability,placental vascular endothelial injury, vascular thrombosis, and
cause RSA.
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